(NASDAQ: HYFT) Mindwalk Holdings's forecast annual revenue growth rate of 33.91% is forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 31.15%, and it is also forecast to beat the US market's average forecast revenue growth rate of 12.98%.
Mindwalk Holdings's revenue in 2026 is $11,676,978.On average, 5 Wall Street analysts forecast HYFT's revenue for 2027 to be $836,562,808, with the lowest HYFT revenue forecast at $755,330,873, and the highest HYFT revenue forecast at $923,773,862. On average, 4 Wall Street analysts forecast HYFT's revenue for 2028 to be $1,028,501,866, with the lowest HYFT revenue forecast at $984,219,017, and the highest HYFT revenue forecast at $1,062,975,223.
In 2029, HYFT is forecast to generate $1,309,754,011 in revenue, with the lowest revenue forecast at $1,239,032,246 and the highest revenue forecast at $1,369,031,369.